BR0014598A - Combinações sinérgicas de um antagonista de receptor nk, e um análogo estrutural gaba - Google Patents

Combinações sinérgicas de um antagonista de receptor nk, e um análogo estrutural gaba

Info

Publication number
BR0014598A
BR0014598A BR0014598-0A BR0014598A BR0014598A BR 0014598 A BR0014598 A BR 0014598A BR 0014598 A BR0014598 A BR 0014598A BR 0014598 A BR0014598 A BR 0014598A
Authority
BR
Brazil
Prior art keywords
receptor antagonist
gaba
synergistic combinations
structural analog
combinations
Prior art date
Application number
BR0014598-0A
Other languages
English (en)
Inventor
John Hughes
Lakhbir Singh
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0014598A publication Critical patent/BR0014598A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: "COMBINAçõES SINéRGICAS DE UM ANTAGONISTA DE RECEPTOR NK, E UM ANáLOGO ESTRUTURAL GABA". A presente invenção proporciona processos para tratamento utilizando combinações sinérgicas de um antagonista de receptor NK~ 1~ e um análogo GABA, e composições e produtos farmacêuticos contendo o antagonista de receptor NK~ 1~ e análogo GABA. A presente invenção também proporciona a utilização de um antagonista de receptor NK~ 1~ e um análogo GABA para a fabricação de um medicamento para o tratamento ou prevenção da dor crónica.
BR0014598-0A 1999-10-07 2000-10-05 Combinações sinérgicas de um antagonista de receptor nk, e um análogo estrutural gaba BR0014598A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07
PCT/EP2000/009858 WO2001024792A1 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Publications (1)

Publication Number Publication Date
BR0014598A true BR0014598A (pt) 2002-06-11

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014598-0A BR0014598A (pt) 1999-10-07 2000-10-05 Combinações sinérgicas de um antagonista de receptor nk, e um análogo estrutural gaba

Country Status (38)

Country Link
EP (2) EP1221950B1 (pt)
JP (2) JP2003510356A (pt)
KR (1) KR20020060192A (pt)
CN (1) CN1387434A (pt)
AP (1) AP2002002501A0 (pt)
AR (1) AR029646A1 (pt)
AT (1) ATE269072T1 (pt)
AU (2) AU7663300A (pt)
BG (1) BG106548A (pt)
BR (1) BR0014598A (pt)
CA (1) CA2385930A1 (pt)
CO (1) CO5280195A1 (pt)
CR (1) CR6614A (pt)
CZ (1) CZ20021116A3 (pt)
DE (1) DE60011650T2 (pt)
DK (1) DK1221950T3 (pt)
EA (1) EA004266B1 (pt)
EE (1) EE200200185A (pt)
ES (1) ES2220542T3 (pt)
GT (1) GT200000166A (pt)
HR (1) HRP20020286A2 (pt)
HU (1) HUP0203466A3 (pt)
IL (1) IL148965A0 (pt)
IS (1) IS6318A (pt)
MA (1) MA26826A1 (pt)
MX (1) MXPA02003484A (pt)
NO (1) NO20021625D0 (pt)
NZ (1) NZ517949A (pt)
OA (1) OA12063A (pt)
PA (1) PA8504301A1 (pt)
PE (1) PE20010708A1 (pt)
PL (1) PL357498A1 (pt)
PT (1) PT1221950E (pt)
SK (1) SK4542002A3 (pt)
TR (1) TR200200913T2 (pt)
UY (1) UY26376A1 (pt)
WO (2) WO2001024792A1 (pt)
ZA (1) ZA200202675B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0934061T6 (en) 1996-07-24 2015-01-26 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
CN1720025A (zh) * 2002-10-08 2006-01-11 兰贝克赛实验室有限公司 加巴喷丁片剂及其制备
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
DE602004003172T2 (de) * 2003-03-21 2007-09-27 Dynogen Pharmaceuticals Inc., Waltham Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
EP2599487B1 (en) 2010-07-30 2015-04-01 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
US20220175707A1 (en) 2019-03-26 2022-06-09 Orion Corporation Pregabalin formulations and use thereof
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
CA2266773A1 (en) * 1996-10-07 1998-04-16 Merck Sharp & Dohme Limited Use of a nk-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
JP2001504848A (ja) * 1996-12-02 2001-04-10 メルク シヤープ エンド ドーム リミテツド 重症不安障害の治療のためのｎｋ−１受容体拮抗薬の使用

Also Published As

Publication number Publication date
PL357498A1 (en) 2004-07-26
PA8504301A1 (es) 2002-08-26
DE60011650T2 (de) 2005-07-14
CA2385930A1 (en) 2001-04-12
GT200000166A (es) 2002-03-30
NZ517949A (en) 2003-08-29
EP1221950A1 (en) 2002-07-17
HUP0203466A3 (en) 2005-03-29
SK4542002A3 (en) 2003-09-11
JP2003510356A (ja) 2003-03-18
MA26826A1 (fr) 2004-12-20
HRP20020286A2 (en) 2003-08-31
IS6318A (is) 2002-03-21
KR20020060192A (ko) 2002-07-16
EE200200185A (et) 2003-04-15
EP1233766A1 (en) 2002-08-28
WO2001024792A9 (en) 2002-09-06
EA200200303A1 (ru) 2002-08-29
ES2220542T3 (es) 2004-12-16
CN1387434A (zh) 2002-12-25
ATE269072T1 (de) 2004-07-15
ZA200202675B (en) 2003-04-15
NO20021625L (no) 2002-04-05
CR6614A (es) 2003-12-04
WO2001024791A1 (en) 2001-04-12
UY26376A1 (es) 2000-12-29
EA004266B1 (ru) 2004-02-26
BG106548A (en) 2002-12-29
WO2001024792A1 (en) 2001-04-12
AP2002002501A0 (en) 2002-06-30
AU7663300A (en) 2001-05-10
OA12063A (en) 2006-05-03
PT1221950E (pt) 2004-08-31
DK1221950T3 (da) 2004-09-20
AU1696201A (en) 2001-05-10
TR200200913T2 (tr) 2002-09-23
AR029646A1 (es) 2003-07-10
HUP0203466A2 (hu) 2003-02-28
CZ20021116A3 (cs) 2003-05-14
CO5280195A1 (es) 2003-05-30
IL148965A0 (en) 2002-11-10
NO20021625D0 (no) 2002-04-05
EP1221950B1 (en) 2004-06-16
DE60011650D1 (de) 2004-07-22
PE20010708A1 (es) 2001-07-27
JP2003510355A (ja) 2003-03-18
MXPA02003484A (es) 2004-09-10

Similar Documents

Publication Publication Date Title
CY1120313T1 (el) Φαρμακευτικη συνθεση για δερματικη χρηση για να θεραπευεται ψωριαση που περιλαμβανει βιταμινη d και κορτικοστεοειδες
IS8807A (is) Notkun á daptómýsíni og lyfjasamsetningar sem innihalda það
WO2003094836A3 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
BR9709915A (pt) Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto
AU2003301190A1 (en) Administration of capsaicinoids
WO2001078698A3 (en) Use of ngf-antagonists for the prevention or treatment of chronic visceral pain
BRPI0414876A (pt) compostos e composições farmcêuticas para prevenção de overdose ou abuso e respectivos usos
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
CA2427227A1 (en) Lactam compound
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
BR0014598A (pt) Combinações sinérgicas de um antagonista de receptor nk, e um análogo estrutural gaba
EP2392322A3 (en) Dosing regimes for trans-clomiphene
MXPA06000705A (es) Combinacion de antagonista del receptor 2 de glutamato metabotropico (mglur2) e inhibidor de acetilcolinesterasa (ache) para tratar trastornos neurologicos agudos y/o cronicos.
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
DE50114474D1 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
GB2331926A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
SE0203817D0 (sv) New composition
BR0116373A (pt) Utilização de tienilciclo-hexilamina, produto, e, composições farmacêuticas
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
BR0104005A (pt) Composição farmacêutica para a prevenção ou para o tratamento de uma doença associada com um excesso de produção de il-2
GB9917290D0 (en) Pharmaceutical composition
WO2002036105A3 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
WO2003066806A3 (en) Therapeutic use of aziridino compounds

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements